Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NI-071 vs Remicade in Rheumatoid Arthritis
NCT02990806Phase 3Completed
- Sponsor
- Nichi-Iko Pharmaceutical
- Start
- Jan 2017
- Primary completion
- May 2019
- Modality
- Monoclonal Antibodies
- Countries
- 8
01
Overview
Phase 3, randomised, double-blind trial of GS07 in rheumatoid arthritis (RA), sponsored by Nichi-Iko Pharmaceutical. Primary endpoints: American College of Rheumatology 20% Response at 22 weeks, Area Under the Serum Concentration-time Curve Interval at 46 weeks and 1 more. Started Jan 2017; status: completed.
02
Drugs
GS07
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT02990806.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02990806.